ArticleDiscover oncology2025
Hsa_circ_0062522 affects the progression and tamoxifen resistance of estrogen receptor-positive breast cancer by targeting miR-3163.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Non-coding RNA-mediated mechanisms underlying tamoxifen resistance in breast cancer.Discover oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultiple circRNAs are abnormally expressed in breast cancer (BC), which may be involved in tumor progression and promote anti-tumor drug resistance.
aimTo explore the effect of hsa_circ_0062522 on the development of estrogen receptor-positive (ER+) breast cancer and tamoxifen (TAM) resistance. MATERIALS AND
methodsThis study collected a total of 112 paired ER + breast cancer tumour tissues and adjacent tissues. The expression of hsa_circ_0062522 and miR-3163 in ER + breast cancer tissues and cells were determined by RT-qPCR. The cell viability, migration and apoptosis of MCF-7 and T-47D were determined by CCK-8, transwell and flow cytometry assays. Spearman correlation analysis and dual luciferase assay were perfprmed to verify the interaction between hsa_circ_0062522 and miR-3163. Establish a mouse model of xenograft with MCF-7 or T-47D cells to study the effect of hsa_circ_0062522 on ER + breast cancer in vivo.
resultsHsa_circ_0062522 was increased, while miR-3163 was decreased in ER + breast cancer tissues and cells. Up-regulation of hsa_circ_0062522 promoted cell viability, cell migration and TAM resistance, but inhibited apoptosis in ER + breast cancer cells. Down-regulation of hsa_circ_0062522 had the opposite effect. Dual luciferase and cell function experiments confirmed that hsa_circ_0062522 affected the progression and TAM resistance of ER + breast cancer by regulating miR-3163. In vivo experiments have demonstrated that silencing hsa_circ_0062522 can reduce the volume and weight of tumors in mice and increase the sensitivity of tumors to TAM.
conclusionHsa_circ_0062522 affects the activity, migration, apoptosis and TAM resistance of ER + breast cancer cells in vitro through miR-3163. In vivo, it influences the volume, weight and TAM sensitivity of tumors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.